Get started
Author

Daniel J. George

Observed name: George, Daniel J.
ORCID: 0000-0001-9168-2307
Observed ORCID: 0000-0001-9168-2307
OpenAlex ID: A5081865770
Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation
2025 · Fred Saad, Andrew J. Armstrong, et al. · Targeted Oncology · 11
PDF
Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale
2024 · Cora N. Sternberg, Stephen J. Freedland, et al. · Clinical Genitourinary Cancer · 6
Real-world intensification beyond androgen deprivation therapy (ADT) in metastatic hormone sensitive prostate cancer (mHSPC) in the United States 2017-2023: An administrative claims database study.
2024 · Amit D Raval, Orsolya Lunacsek, et al. · Journal of Clinical Oncology · 4
Association between decline of neutrophil-to-eosinophil ratio (NER) at week 6 after ipilimumab plus nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma (mRCC).
2022 · Yu-Wei Chen, Matthew D Tucker, et al. · Journal of Clinical Oncology · 2
A Breakthrough From China in a Rare Form of Kidney Cancer
2025 · Daniel J. George, Michael R. Harrison · JAMA Oncology · 1
Real-world outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) receiving guideline-recommended therapies after treatment with 177 Lu-PSMA-617: A real-world prostate cancer disease observation (PRECISION) data platform analysis.
2025 · Xiao X. Wei, Neal D. Shore, et al. · Journal of Clinical Oncology · 1
Pd35-08 Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Pooled Safety Analyses From Randomized Controlled Studies
2022 · James L. Bailen, Fred Saad, et al. · The Journal of Urology · 1
Profiling of exceptional responders (ER) and non-responders (NR) to androgen receptor pathway inhibitors (ARPI) in men with metastatic hormone sensitive and castration resistant prostate cancer.
2025 · Jane McKenzie, Lauren Howard, et al. · Journal of Clinical Oncology
Real-world outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) receiving guideline-recommended therapies after treatment with 177 Lu-PSMA-617: A real-world prostate cancer disease observation (PRECISION) data platform analysis.
2025 · Xiao X. Wei, Neal D. Shore, et al. · Journal of Clinical Oncology
PDF
Suboptimal suppression of serum androgen levels among men treated with apalutamide and abiraterone acetate plus prednisone compared with abiraterone acetate plus prednisone alone.
2025 · Elahe A. Mostaghel, Jennifer A. Freedman, et al. · Journal of Clinical Oncology
PDF
Mp16-01 Efficacy and Safety of Darolutamide Plus Androgen-deprivation Therapy (adt) in Black Patients With Metastatic Hormone-sensitive Prostate Cancer (mhspc) From the Phase 3 Aranote Trial
2025 · Quoc-Dien Trinh, Daniel J. George, et al. · The Journal of Urology
Ip04-33 Improving Outcomes of Patients With Advanced Prostate Cancer Through a Better Understanding of Clinical Factors Contributing to Financial Toxicity: a Qualitative Study
2025 · Samantha Zhu, Jeremy Kurnot, et al. · The Journal of Urology
A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune checkpoint blockade.
2024 · Elshad Hasanov, Hans J. Hammers, et al. · Journal of Clinical Oncology
PDF
Supplemental Figure 2 from Development of a Novel c-MET–Based CTC Detection Platform
2023 · Tian Zhang, Rengasamy Boominathan, et al.
Data from A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
2023 · Andrew J. Armstrong, George J. Netto, et al.
Table S4 from Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
2023 · Daniel J. George, Jean-Francois Martini, et al.
PDF
Supplementary Figure 3 from PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
2023 · Abdallah Flaifel, Wanling Xie, et al.
Supplementary Table from PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
2023 · Abdallah Flaifel, Wanling Xie, et al.
Data from PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
2023 · Abdallah Flaifel, Wanling Xie, et al.
Supplementary Data from A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
2023 · Andrew J. Armstrong, George J. Netto, et al.
Abstract C053: Differences in hallmark gene sets in the Molecular Signatures Database between tumors from African American and White patients
2023 · Muthana Al Abo, Daniel J. George, et al. · Cancer Epidemiology Biomarkers & Prevention
Mp27-16 Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Detailed Safety Analysis From the Randomized Phase 3 Hero Study
2022 · Bryan Mehlhaff, Neal D. Shore, et al. · The Journal of Urology
Development of a Standardized Set of Patient-centered Outcomes for Advanced Prostate Cancer: An International Effort for a Unified Approach
2021 · Basch, Ethan, Bossi, Alberto, et al. · UNC Libraries
Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study
2020 · Vogelzang, Nicholas J., Sweeney, Christopher J., et al. · Carolina Digital Repository (University of North Carolina at Chapel Hill)
PDF
Contributors
2020 · James L. Abbruzzese, Omar Abdel-Wahab, et al. · Elsevier eBooks
Works count: 28
Citation count: 26
H-index: 3
I10-index: 1
Year
Topic
Type